CoChat
Sign Up
Cited by 77

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Plasma dilution improves cognition and attenuates neuroinflammation in old mice

Mehdipour, Melod, Mehdipour, Taha, Skinner, Colin M., Wong, Nathan, Liu, Chao, Chen, Chia-Chien, Jeon, Ok Hee, Zuo, Yi, Conboy, Michael J., Conboy, Irina M.·2021·GeroScience
DOI 10.1007/s11357-020-00297-8PMC PMC8050203
Open this paper in CoChat — free account

Abstract

Our recent study has established that young blood factors are not causal, nor necessary, for the systemic rejuvenation of mammalian tissues. Instead, a procedure referred to as neutral blood exchange (NBE) that resets signaling milieu to a pro-regenerative state through dilution of old plasma, enhanced the health and repair of the muscle and liver, and promoted better hippocampal neurogenesis in 2-year-old mice (Mehdipour et al., Aging 12:8790–8819, 2020). Here we expand the rejuvenative phenotypes of NBE, focusing on the brain. Namely, our results demonstrate that old mice perform much better in novel object and novel texture (whisker discrimination) tests after a single NBE, which is accompanied by reduced neuroinflammation (less-activated CD68+ microglia). Evidence against attenuation/dilution of peripheral senescence-associated secretory phenotype (SASP) as the main mechanism behind NBE was that the senolytic ABT 263 had limited effects on neuroinflammation and did not enhance hippocampal neurogenesis in the old mice. Interestingly, peripherally acting ABT 263 and NBE both diminished SA-βGal signal in the old brain, demonstrating that peripheral senescence propagates to the brain, but NBE was more robustly rejuvenative than ABT 263, suggesting that rejuvenation was not simply by reducing senescence. Explaining the mechanism of the positive effects of NBE on the brain, our comparative proteomics analysis demonstrated that dilution of old blood plasma yields an increase in the determinants of brain maintenance and repair in mice and in people. These findings confirm the paradigm of rejuvenation through dilution of age-elevated systemic factors and extrapolate it to brain health and function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11357-020-00297-8

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Multiple interventions, acting at different levels, can delay or even reverse the aging process.

    “In contrast to the view of aging as an irreversible and unidirectional process akin to an increase in cell entropy, recent studies have demonstrated that multiple interventions, acting at different levels, can delay or even reverse this process [10][11][12][13][14][15][16][17] .”

    From Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming (2023) · cites this paper as [13]

    The Introduction describes slowing or reversing aging as a prominent interpretation of heterochronic-parabiosis studies. The Discussion reports rejuvenative effects from plasma dilution and discusses drug-based approaches, supporting the point that interventions can improve age-related outcomes through different mechanisms. It does not demonstrate reversal of the aging process as a whole; its findings concern particular tissues and brain-related outcomes. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

  • The long-term impact of interventions on whole organisms is still poorly understood.

    “Such interventions have been successful in reducing cell damage and preserving tissue health, but the long-term impact on whole organisms is still poorly understood [11][12][13][14] .”

    From Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming (2023) · cites this paper as [13]

    The Results describe cognitive and neuroinflammation measurements six days after a single plasma exchange in old mice; the proteomics comparison includes human samples collected one month after treatment (Results, Fig. 5). Our copy does not state that the long-term impact of interventions on whole organisms is poorly understood. Searches for long-term outcomes, lifespan, and longitudinal follow-up did not locate that point. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

  • Interventions have been successful in reducing cell damage and preserving tissue health.

    “Such interventions have been successful in reducing cell damage and preserving tissue health, but the long-term impact on whole organisms is still poorly understood [11][12][13][14] .”

    From Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming (2023) · cites this paper as [13]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 89

  1. Conboy IM, Rando TA. Aging, stem cells and tissue regeneration: lessons from muscle. Cell Cycle. 2005;4:407–10. https://doi.org/10.4161/cc.4.3.1518. · DOI · Paper page
  2. Conboy MJ, Conboy IM, Rando TA. Heterochronic parabiosis: historical perspective and methodological considerations for studies of aging and longevity. Aging Cell. 2013;12:525–30. · DOI · Paper page
  3. Conboy IM, Rando TA. Heterochronic parabiosis for the study of the effects of aging on stem cells and their niches. Cell Cycle. 2012;11:2260–7. · DOI · Paper page
  4. Conboy IM, Conboy MJ, Rebo J. Systemic problems: a perspective on stem cell aging and rejuvenation. Aging (Albany NY). 2015;7:754–65. · DOI · Paper page
  5. Bouchard J, Villeda SA. Aging and brain rejuvenation as systemic events. J Neurochem. 2015;132:5–19. https://doi.org/10.1111/jnc.12969. · DOI
  6. Patterson SL. Immune dysregulation and cognitive vulnerability in the aging brain: interactions of microglia, IL-1β, BDNF and synaptic plasticity. Neuropharmacology. 2015;96:11–8. https://doi.org/10.1016/j.neuropharm.2014.12.020. · DOI
  7. Fan X, Wheatley EG, Villeda SA. Mechanisms of hippocampal aging and the potential for rejuvenation. Annu Rev Neurosci. 2017;40:251–72. https://doi.org/10.1146/annurev-neuro-072116-031357. · DOI
  8. Carlson ME, Silva HS, Conboy IM. Aging of signal transduction pathways, and pathology. Exp Cell Res. 2008;314:1951–61. · DOI
  9. Yousef H, Morgenthaler A, Schlesinger C, Bugaj L, Conboy IM, Schaffer DV. Age-associated increase in BMP signaling inhibits hippocampal neurogenesis. Stem Cells. 2015;33:1577–88. https://doi.org/10.1002/stem.1943. · DOI · Paper page
  10. Yousef H, Conboy MJ, Morgenthaler A, Schlesinger C, Bugaj L, Paliwal P, et al. Systemic attenuation of the TGF-β pathway by a single drug simultaneously rejuvenates hippocampal neurogenesis and myogenesis in the same old mammal. Oncotarget. 2015;6:11959–78. https://doi.org/10.18632/oncotarget.3851. · DOI · Paper page
  11. Yousef H, Czupalla CJ, Lee D, Chen MB, Burke AN, Zera KA, et al. Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Nat Med. 2019;25:988–1000. https://doi.org/10.1038/s41591-019-0440-4. · DOI · Paper page
  12. Brun CE, Rudnicki MA. GDF11 and the mythical fountain of youth. Cell Metab. 2015;22:54–6. https://doi.org/10.1016/j.cmet.2015.05.009. · DOI
  13. Duits FH, Hernandez-Guillamon M, Montaner J, Goos JDC, Montañola A, Wattjes MP, et al. Matrix metalloproteinases in Alzheimer’s disease and concurrent cerebral microbleeds. J Alzheimers Dis. 2015;48:711–20. https://doi.org/10.3233/JAD-143186. · DOI · Paper page
  14. Wang XX, Tan MS, Yu JT, Tan L. Matrix metalloproteinases and their multiple roles in Alzheimer’s disease. Biomed Res Int. 2014;2014:908636–8. https://doi.org/10.1155/2014/908636. · DOI · Paper page
  15. Shytikov D, Balva O, Debonneuil E, Glukhovskiy P, Pishel I. Aged mice repeatedly injected with plasma from young mice: a survival study. Biores Open Access. 2014;3:226–32. https://doi.org/10.1089/biores.2014.0043. · DOI
  16. Sha SJ, Deutsch GK, Tian L, Richardson K, Coburn M, Gaudioso JL, et al. Safety, tolerability, and feasibility of young plasma infusion in the plasma for Alzheimer symptom amelioration study: a randomized clinical trial. JAMA Neurol. 2019;76:35–40. https://doi.org/10.1001/jamaneurol.2018.3288. · DOI · Paper page
  17. Chen C-C, Lu J, Yang R, Ding JB, Zuo Y. Selective activation of parvalbumin interneurons prevents stress-induced synapse loss and perceptual defects. Mol Psychiatry. 2018;23:1614–25. https://doi.org/10.1038/mp.2017.159. · DOI
  18. Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process. 2012;13:93–110. https://doi.org/10.1007/s10339-011-0430-z. · DOI · Paper page
  19. Mehdipour M, Etienne J, Chen C-C, Gathwala R, Rehman M, Kato C, et al. Rejuvenation of brain, liver and muscle by simultaneous pharmacological modulation of two signaling determinants, that change in opposite directions with age. Aging (Albany NY). 2019;11:5628–45. https://doi.org/10.18632/aging.102148. · DOI · Paper page
  20. Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. Clin Geriatr Med. 2013;29:737–52. https://doi.org/10.1016/j.cger.2013.07.002. · DOI
  21. van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci. 1999;2:266–70. https://doi.org/10.1038/6368. · DOI · Paper page
  22. Wu HP, Ioffe JC, Iverson MM, Boon JM, Dyck RH. Novel, whisker-dependent texture discrimination task for mice. Behav Brain Res. 2013;237:238–42. https://doi.org/10.1016/j.bbr.2012.09.044. · DOI
  23. Hsu C-C, Serio A, Amdursky N, Besnard C, Stevens MM. Fabrication of hemin-doped serum albumin-based fibrous scaffolds for neural tissue engineering applications. ACS Appl Mater Interfaces. 2018;10:5305–17. https://doi.org/10.1021/acsami.7b18179. · DOI
  24. Lueptow LM. Novel object recognition test for the investigation of learning and memory in mice. J Vis Exp. 2017;55718. https://doi.org/10.3791/55718. · DOI
  25. Lian BSX, Yek AEH, Shuvas H, Abdul Rahman SF, Muniandy K, Mohana-Kumaran N. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines. BMC Res Notes. 2018;11:197. https://doi.org/10.1186/s13104-018-3302-0. · DOI
  26. Wang H, Hong B, Li X, Deng K, Li H, Yan Lui VW, et al. JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer. Oncotarget. 2017;8:86312–24. https://doi.org/10.18632/oncotarget.21146. · DOI
  27. Lin Q-H, Que F-C, Gu C-P, Zhong D-S, Zhou D, Kong Y, et al. ABT-263 induces G(1)/G(0)-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro. Acta Pharmacol Sin. 2017;38:1632–41. https://doi.org/10.1038/aps.2017.78. · DOI
  28. Lee Y-C, Wang L-J, Huang C-H, Shi Y-J, Chang L-S. ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells. Cancer Lett. 2018;432:191–204. https://doi.org/10.1016/j.canlet.2018.06.019. · DOI
  29. Pan J, Li D, Xu Y, Zhang J, Wang Y, Chen M, et al. Inhibition of Bcl-2/xl with ABT-263 selectively kills senescent type II pneumocytes and reverses persistent pulmonary fibrosis induced by ionizing radiation in mice. Int J Radiat Oncol Biol Phys. 2017;99:353–61. https://doi.org/10.1016/j.ijrobp.2017.02.216. · DOI
  30. Chang J, Wang Y, Shao L, Laberge RM, Demaria M, Campisi J, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016;22:78–83. https://doi.org/10.1038/nm.4010. · DOI · Paper page
  31. Yu X, Dobrikov M, Keir ST, Gromeier M, Pastan IH, Reisfeld R, et al. Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. PLoS One. 2019;14:e0210608. · DOI
  32. Yamaguchi R, Perkins G (2012) Finding a panacea among combination cancer therapies. Cancer Res 72:18 LP – 23. https://doi.org/10.1158/0008-5472.CAN-11-3091. · DOI
  33. Heinemann U, Kaufer D, Friedman A. Blood-brain barrier dysfunction, TGFβ signaling, and astrocyte dysfunction in epilepsy. Glia. 2012;60:1251–7. https://doi.org/10.1002/glia.22311. · DOI
  34. Banks WA, Farr SA, Morley JE. Permeability of the blood-brain barrier to albumin and insulin in the young and aged SAMP8 mouse. Journals Gerontol Ser A. 2000;55:B601–6. https://doi.org/10.1093/gerona/55.12.B601. · DOI
  35. Balusu S, Van Wonterghem E, De Rycke R, Raemdonck K, Stremersch S, Gevaert K, et al. Identification of a novel mechanism of blood-brain communication during peripheral inflammation via choroid plexus-derived extracellular vesicles. EMBO Mol Med. 2016;8:1162–83. https://doi.org/10.15252/emmm.201606271. · DOI
  36. Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2017;49:60–8. https://doi.org/10.1016/j.neurobiolaging.2016.08.019. · DOI · Paper page
  37. Bettcher BM, Neuhaus J, Wynn MJ, Elahi FM, Casaletto KB, Saloner R, et al. Increases in a pro-inflammatory chemokine, MCP-1, are related to decreases in memory over time. Front Aging Neurosci. 2019;11:25. https://doi.org/10.3389/fnagi.2019.00025. · DOI
  38. Walton CC, Begelman D, Nguyen W, Andersen JK. Senescence as an amyloid cascade: the amyloid senescence hypothesis. Front Cell Neurosci. 2020;14:129. https://doi.org/10.3389/fncel.2020.00129. · DOI
  39. Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci. 2019;13:363. https://doi.org/10.3389/fncel.2019.00363. · DOI · Paper page
  40. Hong H-S, Maezawa I, Petrlova J, Zhao X-Y, Voss JC, Jin L-W. Tomoregulin (TMEFF2) binds Alzheimer’s disease amyloid-β (Aβ) oligomer and AβPP and protects neurons from Aβ-induced toxicity. J Alzheimers Dis. 2015;48:731–43. https://doi.org/10.3233/JAD-150318. · DOI · Paper page
  41. Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev. 2009;89:607–48. https://doi.org/10.1152/physrev.00031.2008. · DOI
  42. Linnartz B, Wang Y, Neumann H. Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation. Int J Alzheimers Dis. 2010;2010:587463–7. https://doi.org/10.4061/2010/587463. · DOI · Paper page
  43. Siddiqui SS, Matar R, Merheb M, Hodeify R, Vazhappilly CG, Marton J, et al. Siglecs in brain function and neurological disorders. Cells. 2019;8:1125. https://doi.org/10.3390/cells8101125. · DOI · Paper page
  44. Filipovic R, Jakovcevski I, Zecevic N. GRO-α and CXCR2 in the human fetal brain and multiple sclerosis lesions. Dev Neurosci. 2003;25:279–90. https://doi.org/10.1159/000072275. · DOI
  45. Oyagi A, Hara H. Essential roles of heparin-binding epidermal growth factor-like growth factor in the brain. CNS Neurosci Ther. 2012;18:803–10. https://doi.org/10.1111/j.1755-5949.2012.00371.x. · DOI
  46. Steidinger TU, Standaert DG, Yacoubian TA. A neuroprotective role for angiogenin in models of Parkinson’s disease. J Neurochem. 2011;116:334–41. https://doi.org/10.1111/j.1471-4159.2010.07112.x. · DOI
  47. Zheng W, Geng A, Li P, Wang Y, Yuan X. Robo4 regulates the radial migration of newborn neurons in developing neocortex. Cereb Cortex. 2012;22:2587–601. https://doi.org/10.1093/cercor/bhr330. · DOI
  48. Houben E, Hellings N, Broux B. Oncostatin M, an underestimated player in the central nervous system. Front Immunol. 2019;10:1165. https://doi.org/10.3389/fimmu.2019.01165. · DOI
  49. Widenfalk J, Nosrat C, Tomac A, Westphal H, Hoffer B, Olson L (1997) Neurturin and glial cell line-derived neurotrophic factor receptor-β (GDNFR-β), novel proteins related to GDNF and GDNFR-α with specific cellular patterns of expression suggesting roles in the developing and adult nervous system and in peripheral organs. J Neurosci 17:8506 LP – 8519 . https://doi.org/10.1523/JNEUROSCI.17-21-08506.1997. · DOI
  50. Koyama Y. Endothelin systems in the brain: involvement in pathophysiological responses of damaged nerve tissues. Biomol Concepts. 2013;4:335–47. https://doi.org/10.1515/bmc-2013-0004. · DOI
  51. Leiter O, Seidemann S, Overall RW, Ramasz B, Rund N, Schallenberg S, et al. Exercise-induced activated platelets increase adult hippocampal precursor proliferation and promote neuronal differentiation. Stem Cell Reports. 2019;12:667–79. https://doi.org/10.1016/j.stemcr.2019.02.009. · DOI · Paper page
  52. El-Kordi A, Radyushkin K, Ehrenreich H. Erythropoietin improves operant conditioning and stability of cognitive performance in mice. BMC Biol. 2009;7:37. https://doi.org/10.1186/1741-7007-7-37. · DOI
  53. Sheridan GK, Murphy KJ. Neuron–glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open Biol. 2013;3:130181. https://doi.org/10.1098/rsob.130181. · DOI
  54. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008;5:45. https://doi.org/10.1186/1742-2094-5-45. · DOI
  55. Pérez-Martínez L, Jaworski DM (2005) Tissue inhibitor of metalloproteinase-2 promotes neuronal differentiation by acting as an anti-mitogenic signal. J Neurosci 25:4917 LP – 4929. https://doi.org/10.1523/JNEUROSCI.5066-04.2005. · DOI
  56. Gómez-Gaviro MV, Scott CE, Sesay AK, Matheu A, Booth S, Galichet C, et al. Betacellulin promotes cell proliferation in the neural stem cell niche and stimulates neurogenesis. Proc Natl Acad Sci U S A. 2012;109:1317–22. https://doi.org/10.1073/pnas.1016199109. · DOI
  57. Novak U, Walker F, Kaye A. Expression of EGFR-family proteins in the brain: role in development, health and disease. J Clin Neurosci. 2001;8:106–11. https://doi.org/10.1054/jocn.2000.0799. · DOI
  58. Wu H, Li J, Xu D, Zhang Q, Cui T. Growth differentiation factor 5 improves neurogenesis and functional recovery in adult mouse hippocampus following traumatic brain injury. Front Neurol. 2018;9:592. https://doi.org/10.3389/fneur.2018.00592. · DOI
  59. Sullivan AM, O’Keeffe GW. The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson’s disease treatment. J Anat. 2005;207:219–26. https://doi.org/10.1111/j.1469-7580.2005.00447.x. · DOI
  60. Khan S. IGFBP-2 signaling in the brain: from brain development to higher order brain functions. Front Endocrinol (Lausanne). 2019;10:822. https://doi.org/10.3389/fendo.2019.00822. · DOI
  61. Lewitt MS, Boyd GW. The role of insulin-like growth factors and insulin-like growth factor-binding proteins in the nervous system. Biochem insights. 2019;12:1178626419842176–6. https://doi.org/10.1177/1178626419842176. · DOI
  62. Yepes M. Urokinase-type plasminogen activator is a modulator of synaptic plasticity in the central nervous system: implications for neurorepair in the ischemic brain. Neural Regen Res. 2020;15:620–4. https://doi.org/10.4103/1673-5374.266904. · DOI
  63. Merino P, Yepes M (2018) Urokinase-type plasminogen activator induces neurorepair in the ischemic brain. J Neurol Exp Neurosci 4:24–29. https://doi.org/10.17756/jnen.2018-039 · DOI
  64. Cansell C, Denis R, Joly-Amado A, Castel J, Luquet S. Arcuate AgRP neurons and the regulation of energy balance. Front Endocrinol (Lausanne). 2012;3:169. https://doi.org/10.3389/fendo.2012.00169. · DOI
  65. Mikhrina AL, Romanova IV. The role of AGRP in regulating dopaminergic neurons in the brain. Neurosci Behav Physiol. 2015;45:536–41. https://doi.org/10.1007/s11055-015-0107-7. · DOI
  66. Boada M, Ortiz P, Anaya F, Hernández I, Muñoz J, Núñez L, et al. Amyloid-targeted therapeutics in Alzheimer’s disease: use of human albumin in plasma exchange as a novel approach for Aβ mobilization. Drug News Perspect. 2009;22:325–39. · DOI
  67. Loeffler DA. AMBAR, an encouraging Alzheimer’s trial that raises questions. Front Neurol. 2020;11:459. https://doi.org/10.3389/fneur.2020.00459. · DOI
  68. Boada M, Anaya F, Ortiz P, Olazarán J, Shua-Haim JR, Obisesan TO, et al. Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-β concentrations and cognition outcomes in Alzheimer’s disease patients: a multicenter, randomized, controlled clinical trial. J Alzheimers Dis. 2017;56:129–43. https://doi.org/10.3233/JAD-160565. · DOI · Paper page
  69. Cuberas-Borrós G, Roca I, Boada M, Tárraga L, Hernández I, Buendia M, et al. Longitudinal neuroimaging analysis in mild-moderate Alzheimer’s disease patients treated with plasma exchange with 5% human albumin. J Alzheimers Dis. 2018;61:321–32. https://doi.org/10.3233/JAD-170693. · DOI
  70. Boada M, López O, Núñez L, Szczepiorkowski ZM, Torres M, Grifols C, et al. Plasma exchange for Alzheimer’s disease Management by Albumin Replacement (AMBAR) trial: study design and progress. Alzheimer’s Dement (New York, N Y). 2019;5:61–9. https://doi.org/10.1016/j.trci.2019.01.001. · DOI · Paper page
  71. Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, Stout MB, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016;15:428–35. https://doi.org/10.1111/acel.12445. · DOI · Paper page
  72. Wang L-J, Liou L-R, Shi Y-J, Chiou J-T, Lee Y-C, Huang C-H, et al. Albendazole-induced SIRT3 upregulation protects human leukemia K562 cells from the cytotoxicity of MCL1 suppression. Int J Mol Sci. 2020;21:3907. https://doi.org/10.3390/ijms21113907. · DOI
  73. Ohgino K, Terai H, Yasuda H, Nukaga S, Hamamoto J, Tani T, et al. Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small cell lung cancer cells. Cancer Sci n/a. 2020;111:3793–801. https://doi.org/10.1111/cas.14569. · DOI
  74. Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, et al. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020;11:443. https://doi.org/10.1038/s41419-020-2646-2. · DOI
  75. Morimoto Y, Takada K, Takeuchi O, Watanabe K, Hirohara M, Hamamoto T, et al. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2. Mol Cell Biochem. 2020;472:187–98. https://doi.org/10.1007/s11010-020-03796-6. · DOI
  76. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC, et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene. 2008;27:6646–56. https://doi.org/10.1038/onc.2008.259. · DOI
  77. Vogler M, Dickens D, Dyer MJS, Owen A, Pirmohamed M, Cohen GM. The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun. 2011;408:344–9. https://doi.org/10.1016/j.bbrc.2011.04.043. · DOI
  78. Marschallinger J, Schäffner I, Klein B, Gelfert R, Rivera FJ, Illes S, et al. Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. Nat Commun. 2015;6:8466. https://doi.org/10.1038/ncomms9466. · DOI
  79. Krukowski K, Chou A, Feng X, Tiret B, Paladini M-S, Riparip L-K, et al. Traumatic brain injury in aged mice induces chronic microglia activation, synapse loss, and complement-dependent memory deficits. Int J Mol Sci. 2018;19:3753. https://doi.org/10.3390/ijms19123753. · DOI
  80. Chou A, Krukowski K, Morganti JM, Riparip L-K, Rosi S. Persistent infiltration and impaired response of peripherally-derived monocytes after traumatic brain injury in the aged brain. Int J Mol Sci. 2018;19:1616. https://doi.org/10.3390/ijms19061616. · DOI
  81. Hsieh CL, Niemi EC, Wang SH, Lee CC, Bingham D, Zhang J, et al. CCR2 deficiency impairs macrophage infiltration and improves cognitive function after traumatic brain injury. J Neurotrauma. 2014;31:1677–88. https://doi.org/10.1089/neu.2013.3252. · DOI · Paper page
  82. Desale SE, Chinnathambi S. Role of dietary fatty acids in microglial polarization in Alzheimer’s disease. J Neuroinflammation. 2020;17:93. https://doi.org/10.1186/s12974-020-01742-3. · DOI
  83. Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener. 2017;12:50. https://doi.org/10.1186/s13024-017-0192-x. · DOI · Paper page
  84. Scott G, Hellyer PJ, Ramlackhansingh AF, Brooks DJ, Matthews PM, Sharp DJ. Thalamic inflammation after brain trauma is associated with thalamo-cortical white matter damage. J Neuroinflammation. 2015;12:224. https://doi.org/10.1186/s12974-015-0445-y. · DOI
  85. Norden DM, Godbout JP. Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol. 2013;39:19–34. https://doi.org/10.1111/j.1365-2990.2012.01306.x. · DOI · Paper page
  86. Kanaan NM, Kordower JH, Collier TJ. Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys. Neurobiol Aging. 2010;31:937–52. https://doi.org/10.1016/j.neurobiolaging.2008.07.006. · DOI
  87. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461–7. https://doi.org/10.1016/S0140-6736(01)05625-2. · DOI · Paper page
  88. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun. 2011;25:181–213. https://doi.org/10.1016/j.bbi.2010.10.015. · DOI · Paper page
  89. Takahashi Y, Yu Z, Sakai M, Tomita H. Linking activation of microglia and peripheral monocytic cells to the pathophysiology of psychiatric disorders. Front Cell Neurosci. 2016;10. https://doi.org/10.3389/fncel.2016.00144. · DOI

Cited by

Sorted by citations

Metadata

Authors
Mehdipour, M., Mehdipour, T., Skinner, C. M., Wong, N., Liu, C., Chen, C.-C., Jeon, O. H., Zuo, Y., Conboy, M. J., & Conboy, I. M.
Venue
GeroScience
Publisher
Springer Science and Business Media LLC
Published
2020-11-15
Volume
43
Issue
1
Pages
1-18
ISSN
  • 2509-2715
  • 2509-2723
DOI
10.1007/s11357-020-00297-8
PMC
PMC8050203
Cited by
77
References
18
Language
en
Licence
Funders
National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review